Agendia, Inc.’s BluePrint was recently included in the latest version of German Gynecological Oncology Group (AGO) guidelines for chemotherapy decision making. AGO is comprised of gynecological ...

The US Food and Drug Administration (FDA) has approved a new genetic test that could help patients with early-stage breast cancer predict their chance of relapse within 5 or 10 years, information ...

We acknowledge the financial support of Applied Biosystems, Agendia BV, the March of Dimes and the Juvenile Diabetes Research Foundation, which made it possible for the content to be freely available.

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

NICE recommended EndoPredict, Prosigna, and Oncotype DX for node-negative breast cancer only, but the new guidance includes lymph node-positive disease.

The test is offered as an off-site service. In Europe, samples are analysed at the Agendia laboratory in the Netherlands. Results are available within 10 days of submitting the sample. Oncotype DX ...